CompletedNot Applicable

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)

United States1,753 participantsStarted 2019-06-14

Plain-language summary

The purpose of this study is to determine if a search strategy of searching for an HLA-matched unrelated donor for allogeneic transplantation if possible then an alternative donor if an HLA-matched unrelated donor is not available versus proceeding directly to an alternative donor transplant will result in better survival for allogeneic transplant recipients within 2 years after study enrollment.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients of all ages with AML, ALL, MDS, NHL, HL, AA, or SCD are eligible.
✓. Any planned conditioning regimen and GVHD prophylaxis approach is eligible.
✓. Patients must be considered suitable allogeneic transplant candidates at the time of enrollment based on medical history, physical examination, and available laboratory tests. Specific testing for organ function is not required for eligibility but, if available, these tests should be used by the treating physician to judge transplant suitability.
✓. Patient and physician must intend to proceed with allogeneic HCT within the next 6 months if a suitable donor is identified.
✓. Center plans to follow the algorithm for alternative donor identification: (a) for subjects who are Very Likely to find a MUD, attempt to identify a matched unrelated donor; (b) for a subjects who are Very Unlikely to find a MUD, proceed expeditiously to a haploidentical, cord blood or mismatched unrelated donor.
✓. Signed informed consent, and assent if applicable. Consent may be signed prior to completion of family typing but patients will only be considered evaluable upon confirmation that there is no suitable HLA-identical or 1 allele or antigen mismatched related donor available.

Exclusion criteria

✕. Prior allogeneic HCT (prior autologous transplant is allowed)
✕. Previous formal unrelated donor search

What they're measuring

Overall Survival for MUD Very Likely and MUD Very Unlikely Arms

Timeframe: 2 years

Trial details

NCT IDNCT03904134

SponsorCenter for International Blood and Marrow Transplant Research

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2025-01-06

View on ClinicalTrials.gov More Acute Myeloid Leukemia trials